Articles

Poll

Podcasts

Slideshows

Videos

The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.

FDA Accepts Xanomeline-Trospium Drug Application for Schizophrenia Treatment

In a new study, the highest socioeconomic group was associated with lower morality rates for all-cause mortality, lower morality from natural causes, and higher mortality from external causes. Although the data does not show a significant link between the role of socioeconomic position with the mortality rate among people with mental disorders.

Study Explores the Socioeconomic Position Role in the Association Between Mental Disorders, Mortality

From 2018 to 2021, the deaths among U.S. pregnant and postpartum women aged 35 – 44 years old more than tripled, a new study found.

Morality Rates of Pregnancy and Postpartum Drug Increases During COVID-19 Pandemic

At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.

Long-Term ADHD Medication Use Linked to Potential Risk of Cardiovascular Diseases

After years 1, 3, and 5, patients with diabetic retinopathy patients had increased odds of depression and suicide, patients with glaucoma had increased odds for all mental health conditions with higher odds for suicide or suicide ideation, and patients with AMD had increased odds for depression.

Vision Impairment Associated with Developing Mental Health Conditions

Children of mothers in minority group were associated with a higher likelihood of ASD diagnosis, but only children of White mothers had ASD associated with neighborhood disadvantages.

Neighborhood Disadvantages Do Not Influence Minority Children’s High Autism Spectrum Diagnoses

Ryan Oakley, MD, takes a closer look at the recent history of ketamine in depression. He also explores the differences between ketamine and esketamine.

Ketamine for the Treatment of MDD

Eveleigh Wagner, MD, discusses the role of electroconvulsive therapy and transcranial magnetic stimulation in depression treatment.

Interventional Treatment Options for Patients: ECT, VNS, and TMS

Brent Necaise, MD, reviews incidence and risk factors of depression, as well as the challenges associated with treatment.

The Impact of Depression and Treatment Overview

A new study found that 25% of PSG-PTSD were related to metabolic traits.

PTSD Linked to Genetic Cardiometabolic, Respiratory, Digestive Conditions

PTSD

Addiction

Addiction medicine condition center page, resources on the topics of medical news and expert insight into clinical addiction can be found. Content includes articles, interviews, videos, podcasts, and breaking news on addiction therapy research, treatment, and drug development.

ADHD

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.

Bipolar Disorder

The HCPLive bipolar disorder page is a resource for medical news and expert insights on BPD. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for bipolar disease, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.